Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + Osimertinib in EGFR-mutant Advanced NSCLC
NCT07376382Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 3, randomised, open-label trial of CPO301 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Progression Free Survival evaluated by IRC up to 3.5 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07376382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376382.